Abivax reports excellent one-year efficacy and safety data of abx464 phase 2b maintenance trial in ulcerative colitis
“We are very pleased with the results of the phase 2b maintenance study with ABX464 after the first year of continued daily treatment"
**Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax
-
Interim analysis demonstrates best-in-class clinical remission in 55.3% of 217 ulcerative colitis (UC) patients (full analysis set) after 48 weeks of once-daily oral 50mg ABX464
-
Moreover, in the subgroup of patients who had at least a clinical response after the 8-week induction study (n=121), 65.3% achieved clinical remission during the first year of maintenance treatment (full analysis set)
-
Endoscopic improvement and endoscopic remission at week 48 achieved by 61.8% and 33.6% of the patients respectively (full analysis set)
-
Good safety and tolerability profile supports chronic use of ABX464 Final preparations to launch ABX464 global pivotal phase 3 clinical program in UC ongoing, inclusion of first patients is expected in Q3 2022